




The relative strengths and weaknesses of Xeris Biopharma Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Xeris Biopharma Holdings Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 8.8% points. The greatest weakness of Xeris Biopharma Holdings Inc is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 118% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 75% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	167,662
Cost of Goods Sold	0
Intangible Assets	121,780
Liabilities, Current	100,443
Liabilities, Non-Current	252,232
Other Assets	28,056
Other Compr. Net Income	0
Other Expenses	45,407
Other Liabilities	0
Other Net Income	-23,458
Other Revenues	203,070
Property and Equipment	5,562
Research and Development	25,560
Selling, General and Administrative Expense	163,481

Output Variable	Value in 1000 USD
Assets	323,060
Liabilities	352,675
Expenses	234,448
Revenues	203,070
Stockholders Equity	-29,615
Net Income	-54,836
Comprehensive Net Income	-54,836
BaseVar	568,356
ECR before LimitedLiability	-35%
Economic Capital Ratio	140%